Comparison
Alpha-GPC vs GHRP-2
Side-by-side of Alpha-GPC and GHRP-2. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-GPC
Alpha GPC supplement profile: 300 to 600 mg dosage, acetylcholine synthesis, attention and reaction-time evidence, side effects, and choline donor comparisons.
GHRP-2
GHRP-2 peptide (pralmorelin, KP-102) is a synthetic hexapeptide ghrelin-receptor agonist that triggers pulsatile growth hormone release via the pituitary.
Effects at a glance
Alpha-GPC
- •Choline donor supplement, roughly 40% choline by weight; crosses blood-brain barrier efficiently
- •Replicated small gains in attention and reaction time at 300 to 600 mg in healthy adults
- •Standard prescription cognitive medication in much of Europe (Gliatilin) at 1,200 mg/day for vascular cognitive impairment
- •ASCOMALVA trial (n=210) showed cognitive preservation when added to donepezil over 24 months
- •Increases acute power output (~14%, single trial) and transient growth hormone secretion at 600 mg
- •TMAO production raises a contested cardiovascular concern at chronic high doses
GHRP-2
- •Hexapeptide ghrelin-receptor agonist that stimulates pulsatile GH release within 15 to 30 minutes
- •Strongest appetite signal among GHRPs at standard doses; centrally mediated via NPY/AgRP
- •Produces measurable cortisol and prolactin rise (more than ipamorelin, less than GHRP-6)
- •Approved in Japan as pralmorelin for GH-deficiency diagnostic provocation; not FDA approved
- •Anecdotal protocols use 100 to 300 mcg subcutaneously 2 to 3 times daily on an empty stomach
- •Banned by WADA under S2; detection methods validated in accredited labs
Side-by-side
| Attribute | Alpha-GPC | GHRP-2 |
|---|---|---|
| Category | supplement | peptide |
| Also known as | L-Alpha glycerylphosphorylcholine, choline alfoscerate, GPC, alpha-glyceryl phosphorylcholine | Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102, GPA-748 |
| Half-life (hr) ↗ | 4 | 0.5 |
| Typical dose (mg) ↗ | 600 | 0.1 |
| Dosing frequency | 1 to 3 times daily | 2-3x daily |
| Routes | oral | subcutaneous, intranasal, intravenous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 2 | 0.5 |
| Molecular weight | 257.22 | 817.97 |
| Molecular formula | C8H20NO6P | C45H55N9O6 |
| Mechanism | Hydrolyzed to free choline and glycerophosphate after absorption; choline supports acetylcholine and phosphatidylcholine synthesis in CNS. | Hexapeptide agonist of the growth-hormone secretagogue receptor (GHS-R1a). Suppresses hypothalamic somatostatin tone and stimulates pituitary somatotrophs, producing a pulsatile GH release with secondary cortisol, prolactin, and ACTH elevation. |
| Legal status | Dietary supplement (US); prescription medication in much of Europe | Not FDA approved; approved in Japan as pralmorelin (diagnostic); research-use-only grey market in US/EU; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement | Not scheduled in US (research chemical); approved diagnostic in Japan |
| Pregnancy | Insufficient data; choline generally recommended in pregnancy | Insufficient data; not recommended |
| CAS | 28319-77-9 | 158861-67-7 |
| PubChem CID | 71920 | 9919072 |
| Wikidata | Q411478 | Q7235681 |
Safety profile
Alpha-GPC
Common side effects
- mild GI upset
- headache
- dizziness
- occasional insomnia with evening dosing
Contraindications
- established cardiovascular disease (TMAO concern)
- concurrent strong anticholinergic therapy
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors (donepezil): additive cholinergic effect, basis for ASCOMALVA protocol(minor)
- scopolamine: partial counteraction of anticholinergic effect(minor)
GHRP-2
Common side effects
- acute hunger
- head pressure or flushing
- water retention
- vivid dreams
- tingling at injection site
- transient lethargy
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- severe insulin resistance
Interactions
- CJC-1295: synergistic GH release; commonly co-administered for larger pulse(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response and amplify cortisol load(moderate)
Which Should You Take?
Alpha-GPC comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. GHRP-2 is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Alpha-GPC.
- → If your priority is athletic performance, pick Alpha-GPC.
- → If your priority is growth-hormone axis, pick GHRP-2.
- → If your priority is post-training recovery, pick GHRP-2.
Edge case: If you want to avoid research-only / gray-market sourcing, Alpha-GPC is the more accessible choice.
Default choice: Alpha-GPC. Lower friction to source, and broader goal coverage. Reach for GHRP-2 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-GPC and GHRP-2?
Alpha-GPC and GHRP-2 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-GPC or GHRP-2?
Alpha-GPC half-life is 4 hours; GHRP-2 half-life is 0.5 hours.
Can you stack Alpha-GPC with GHRP-2?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper